Multiple reports have also demonstrated that CHIP is detectable in up to 30% of patients with non-Hodgkin lymphoma (NHL) at the time of ASCT and is associated with increased risk of TMN and non-relapse mortality19–21. The gene discussed is STUB1; the disease is non-Hodgkin lymphoma.